Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG)

被引:102
作者
Rüffer, JU
Flechtner, H
Tralls, P
Josting, A
Sieber, M
Lathan, B
Diehl, V
机构
[1] TAKEPART, Dept Internal Med 1, D-50677 Cologne, Germany
[2] Univ Cologne, Clin Child & Adolescent Psychiat & Psychotherapy, D-50924 Cologne, Germany
关键词
fatigue; Hodekin's lymphoma; long-term sequelae; quality of life;
D O I
10.1016/S0959-8049(03)00545-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although treatment regimens for Hodgkin's lymphoma have become more sophisticated, little is known about the prevalence of fatigue in long-term survivors. Therefore, we investigated the fatigue status of long-term survivors of Hodgkin's lymphoma and a control group using a pre-validated questionnaire. In 1995/1996, we contacted 1981 patients, who were enrolled in the German Hodgkin Studies HID 1-6. All patients were treated according to the treatment protocols HD1-3 (1981-1988) and HD 4-6 (1988-1993). The patients with a current status of complete remission were asked to complete a quality-of-life (QoL) questionnaire (European Organisation for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ C-30)) and a fatigue questionnaire (Multidimensional Fatigue Inventory (MFI)). The results were compared with the data from 935 controls, matched for age, gender and living area. Eight-hundred and eighteen questionnaires from the patients were available for analysis. The median time between the end of treatment and completing the questionnaire is 5.2 years. Fatigue levels of patients with Hodgkin's lymphonia are high. even years after treatment. Fatigue dimensions are significantly influenced by several clinical and non-clinical factors. Fatigue levels of Hodgkin's lymphoma patients are significantly higher than those of the control group. Further investigations are warranted to explore the effectiveness of treatment strategies for fatigue. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2179 / 2186
页数:8
相关论文
共 27 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Response rates to mail surveys published in medical journals [J].
Asch, DA ;
Jedrziewski, MK ;
Christakis, NA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (10) :1129-1136
[3]   THE EORTC QLQ-LC13 - A MODULAR SUPPLEMENT TO THE EORTC CORE QUALITY-OF-LIFE QUESTIONNAIRE (QLQ-C30) FOR USE IN LUNG-CANCER CLINICAL-TRIALS [J].
BERGMAN, B ;
AARONSON, NK ;
AHMEDZAI, S ;
KAASA, S ;
SULLIVAN, M .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) :635-642
[4]   PSYCHOSOCIAL OUTCOMES OF CANCER - A COMPARATIVE-ANALYSIS OF HODGKINS-DISEASE AND TESTICULAR CANCER [J].
BLOOM, JR ;
FOBAIR, P ;
GRITZ, E ;
WELLISCH, D ;
SPIEGEL, D ;
VARGHESE, A ;
HOPPE, R .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :979-988
[5]  
BLOOM JR, 1991, ADV MED SOCIOLOGY, V2, P95
[6]  
Cella D F, 1992, J Palliat Care, V8, P8
[7]  
Cella D F, 1995, Oncology (Williston Park), V9, P47
[8]  
CHAO NJ, 1992, BLOOD, V80, P825
[9]  
COPELAND DR, 1986, TEX MED, V82, P46
[10]   FACTORIAL INVARIANCE ACROSS GENDER FOR PRIMARY SYMPTOM DIMENSIONS OF SCL-90 [J].
DEROGATIS, LR ;
CLEARY, PA .
BRITISH JOURNAL OF SOCIAL AND CLINICAL PSYCHOLOGY, 1977, 16 (NOV) :347-356